Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With XELOX and Bevacizumab Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT07854964Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Oct 2026
- Primary completion
- May 2030
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in rectal cancer, sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07854964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854964.